Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Nonalcoholic Steatohepatitis (NASH): Update Bulletin # 3 [February 2019]

Product Code:
596201015
Publication Date:
February 2019
Format:
PDF
Price:
£1,140

Topics covered include expert opinions on: GENFIT’s announcement of the initiation of a Phase II proof-of-concept clinical trial evaluating nitazoxanide in patients with NASH-induced fibrosis; Madrigal Pharmaceuticals’ publication of positive data for MGL-3196, a novel thyroid hormone receptor (THR) β-selective agonist, from a double-blind, placebo-controlled 36-week Phase II study in patients with biopsy-proven NASH; and Cirius Therapeutics’ announcement of positive interim data from the Phase IIb EMMINENCE study evaluating MSDC-0602K in patients diagnosed with NASH with fibrosis.

Business Questions:

• How do KOLs view the potential for nitazoxanide as an antifibrotic agent in NASH?
• Will nitazoxanide be considered for use as a monotherapy or in combination with other agents?
• Based on the new Phase II data, to what extent does MGL-3196 hold promise as a treatment in NASH?
• Do KOLs predict MGL-3196 will be used as a monotherapy or in combination?
• According to KOLs what is the likelihood of MGL-3196 reaching the market?
• What are KOL reactions to the EMMINENCE trial of MSDC-0602K?
• Which patients do KOLs predict MSDC-0602K will be considered for use in?
• What are KOLs safety concerns for MSDC-0602K?
• According to KOLs will MSDC-0602K be used as monotherapy or in combination with other agents to treat NASH?




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved